Hints and tips:
Related Special Reports
...The latest purchasing rules represent China’s most significant step yet to build up domestic substitutes for foreign technology and echo moves in the US as tensions increase between the two countries....
...The ruling came after Escobar Inc, the company set up by his brother, filed an application in 2021 with the European Union Intellectual Property Office (EUIPO) for registration of the word sign Pablo Escobar...
...A top EU court has ruled that the name of the dead Colombian drug kingpin Pablo Escobar cannot be registered as a trademark in the EU....
.... ©2024 Nikkei Inc. All rights reserved....
...But within a year of the US Food and Drug Administration’s 2021 approval of the weight-loss drugs known as GLP-1 agonists, the threat of them breaking WW’s business model became clear....
...Then, GLP-1 anti-obesity drugs hit the market, long-time spokesperson and board member Oprah Winfrey announced her departure, and the company’s credit rating was downgraded....
.... ©2023 Nikkei Inc....
...It acquired obesity drug developer Carmot Therapeutics for $2.7bn....
...The drug is not yet approved in the US or Europe....
...Drugs of the GLP-1 group suppress appetite with remarkable effectiveness. Weight loss success stories have resonated in Wall Street and the C-suite....
...AbbVie’s Humira, used for a range of autoimmune diseases, became the world’s best-selling drug but has recently had its market exclusivity expire....
...It may be almost 2024, but an echo of the late 1980s lingers. On Monday, US Steel announced that it would sell itself to Nippon Steel of Japan at an enterprise value of $15bn....
...J&J’s medtech division has outstripped the growth of the company’s drugs and diagnostics business, generating $30.4bn in sales last year, or 35 per cent of group revenues....
.... ©2023 Nikkei Inc. All rights reserved....
...Its struggles have weighed on other regional US lenders, in an echo of the pressure the sector came under last year following the failure of Silicon Valley Bank....
...know: business Novo Nordisk announced a €1bn deal for a German biotech developing therapies to treat heart disease, as the Danish group seeks to branch out from its blockbuster diabetes and weight loss drugs...
...In the US, the Food and Drug Administration in late 2021 approved emergency use for certain categories of patients....
...In an echo of the “Tesla-financial complex” — and an earlier mania for any stocks even vaguely tied to blockchain technology — any association with AI in general and Nvidia specifically can lift a stock,...
...Novo Nordisk sells Wegovy and Ozempic, a diabetes medicine often prescribed off-label for weight loss, while Eli Lilly recently secured approval of Zepbound, its obesity drug....
...If the sight of a drug-fuelled Freddy trying to placate a thug by dancing in a chicken costume like a coq-au-coke doesn’t do it for you, then I don’t think anything here will....
...Avid Bioservices, a small-cap company that helps develop and manufacture drugs for pharmaceutical companies, filed this with the SEC yesterday: On February 29, 2024, Avid Bioservices, Inc....
...The US Food and Drug Administration in late 2021 gave a severely restricted emergency approval, making it a treatment available to those for whom other drugs were not recommended....
...Eli Lilly’s strong performance in particular — its stock has almost doubled over the past year on the back of strong demand for new weight-loss drugs — highlights the fact that there are at least some themes...
...MSD helped transform cancer care with its drug Keytruda, which harnessed the immune system to tackle tumours....
International Edition